Hunt Peter W, Sinclair Elizabeth, Rodriguez Benigno, Shive Carey, Clagett Brian, Funderburg Nicholas, Robinson Janet, Huang Yong, Epling Lorrie, Martin Jeffrey N, Deeks Steven G, Meinert Curtis L, Van Natta Mark L, Jabs Douglas A, Lederman Michael M
Department of Medicine, University of California San Francisco.
Department of Medicine, Case Western Reserve University, Cleveland, Ohio.
J Infect Dis. 2014 Oct 15;210(8):1228-38. doi: 10.1093/infdis/jiu238. Epub 2014 Apr 21.
While inflammation predicts mortality in treated human immunodeficiency virus (HIV) infection, the prognostic significance of gut barrier dysfunction and phenotypic T-cell markers remains unclear.
We assessed immunologic predictors of mortality in a case-control study within the Longitudinal Study of the Ocular Complications of AIDS (LSOCA), using conditional logistic regression. Sixty-four case patients who died within 12 months of treatment-mediated viral suppression were each matched to 2 control individuals (total number of controls, 128) by duration of antiretroviral therapy-mediated viral suppression, nadir CD4(+) T-cell count, age, sex, and prior cytomegalovirus (CMV) retinitis. A similar secondary analysis was conducted in the SCOPE cohort, which had participants with less advanced immunodeficiency.
Plasma gut epithelial barrier integrity markers (intestinal fatty acid binding protein and zonulin-1 levels), soluble CD14 level, kynurenine/tryptophan ratio, soluble tumor necrosis factor receptor 1 level, high-sensitivity C-reactive protein level, and D-dimer level all strongly predicted mortality, even after adjustment for proximal CD4(+) T-cell count (all P ≤ .001). A higher percentage of CD38(+)HLA-DR(+) cells in the CD8(+) T-cell population was a predictor of mortality before (P = .031) but not after (P = .10) adjustment for proximal CD4(+) T-cell count. Frequencies of senescent (defined as CD28(-)CD57(+) cells), exhausted (defined as PD1(+) cells), naive, and CMV-specific T cells did not predict mortality.
Gut epithelial barrier dysfunction, innate immune activation, inflammation, and coagulation-but not T-cell activation, senescence, and exhaustion-independently predict mortality in individuals with treated HIV infection with a history of AIDS and are viable targets for interventions.
虽然炎症可预测接受治疗的人类免疫缺陷病毒(HIV)感染者的死亡率,但肠道屏障功能障碍和表型T细胞标志物的预后意义仍不明确。
在艾滋病眼部并发症纵向研究(LSOCA)的一项病例对照研究中,我们使用条件逻辑回归评估了死亡率的免疫预测指标。64例在治疗介导的病毒抑制后12个月内死亡的病例患者,根据抗逆转录病毒治疗介导的病毒抑制持续时间、最低CD4(+) T细胞计数、年龄、性别和既往巨细胞病毒(CMV)视网膜炎情况,分别与2名对照个体(对照总数为128名)进行匹配。在SCOPE队列中进行了类似的二次分析,该队列参与者的免疫缺陷程度较轻。
血浆肠道上皮屏障完整性标志物(肠道脂肪酸结合蛋白和闭合蛋白-1水平)、可溶性CD14水平、犬尿氨酸/色氨酸比值、可溶性肿瘤坏死因子受体1水平、高敏C反应蛋白水平和D-二聚体水平均强烈预测死亡率,即使在调整了近端CD4(+) T细胞计数后也是如此(所有P≤0.001)。CD8(+) T细胞群体中较高比例的CD38(+)HLA-DR(+)细胞在调整近端CD4(+) T细胞计数之前是死亡率的预测指标(P = 0.031),但调整后则不是(P = 0.10)。衰老(定义为CD28(-)CD57(+)细胞)、耗竭(定义为PD1(+)细胞)、初始和CMV特异性T细胞的频率不能预测死亡率。
肠道上皮屏障功能障碍、先天性免疫激活、炎症和凝血——而非T细胞激活、衰老和耗竭——可独立预测有艾滋病病史的接受治疗的HIV感染者的死亡率,并且是可行的干预靶点。